Baird Reiterates an 'Outperform' on NewLink Genetics (NLNK); Reinvigorated Bullishness Despite Recent Run

Baird reiterates an 'Outperform' on NewLink Genetics (NASDAQ: NLNK) price target of $17.00 (from $10.00).

Analyst, Christopher J. Raymond, said, "Reiterate rating and raising PT after investigators presented updated HyperAcute Pancreas Phase II data showing impressive 2- and 3-year survival data and perhaps most importantly a widening benefit over expected results over time – perhaps confirming a cornerstone immunotherapy premise. Combining this with signals that the Hyperacute Pancreas Phase III trial is well ahead of enrollment schedule and we continue to recommend purchase of this somewhat “under-the-radar” name."

For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.

Shares of NewLink Genetics closed at $12.53 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• Travel Food Services (TRAVELFO:IN) PT Raised to INR1,600 at ICICI Securities